Boehringer’s Obesity Drug Achieves 16.6% Weight Loss in Trial; Further Data Pending
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Boehringer’s investigational obesity drug demonstrated a 16.6% weight loss in a clinical trial, outperforming many existing treatments. However, addit...
Eli Lilly has partnered with AI-focused biotech Profluent to develop advanced gene editors capable of inserting entire genes into patients. The deal i...